Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 3/20 | 0.49 |
| ▸ | HTR2A | P28223 | 1/20 | 0.49 |
| ▸ | HTR2B | P41595 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | USP2 | O75604 | 1/20 | 0.44 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.43 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.43 |
| ▸ | FABP7 | O15540 | 1/20 | 0.43 |
| ▸ | FABP3 | P05413 | 1/20 | 0.43 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.43 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.42 |
| ▸ | DRD2 | P14416 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17356792 | 1.00 | HTR2C (0.49) | HTR2CHTR2AHTR2BMEN1KMT2A | |
| SCHEMBL17356800 | 0.96 | HTR2C (0.49) | HTR2CHTR2AHTR2BMEN1KMT2A | |
| SCHEMBL12345359 | 0.89 | HTR2C (0.51) | HTR2CHTR2AHTR2BMEN1KMT2A | |
| SCHEMBL17356788 | 0.84 | HTR2C (0.50) | HTR2CHTR2AHTR2BMEN1KMT2A | |
| SCHEMBL12875534 | 0.81 | HTR2C (0.59) | HTR2CHTR2AHTR2BMEN1KMT2A | |
| SCHEMBL1643779 | 0.81 | HTR2C (0.51) | HTR2CHTR2AHTR2BMEN1KMT2A | |
| SCHEMBL9278538 | 0.81 | HTR2C (0.47) | HTR2CHTR2AHTR2BMEN1KMT2A | |
| SCHEMBL1643778 | 0.81 | HTR2C (0.51) | HTR2CHTR2AHTR2BMEN1KMT2A | |
| SCHEMBL17685334 | 0.81 | KDM1A (0.37) | HTR2CHTR2AHTR2BMEN1KMT2A | |
| SCHEMBL9278530 | 0.81 | HTR2C (0.47) | HTR2CHTR2AHTR2BMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8093302-B2 | Substituted tetralins as selective estrogen receptor-β agonists | ELI LILLY AND COMPANY (US) | 2012-01-10 | — | — | US | disclosed |
| US-20100249075-A1 | SUBSTITUTED TETRALINS AS SELECTIVE ESTROGEN RECEPTOR-BETA AGONISTS | ELI LILLY AND COMPANY (US) | 2010-09-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100249075-A1 | SUBSTITUTED TETRALINS AS SELECTIVE ESTROGEN RECEPTOR-BETA AGONISTS | ESR2, ERLIN1, ESRRG | HTR2C 356/4885HTR2A 404/4885HTR2B 372/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.